Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06183931 · ClinicalTrials.gov registry record · Phase 3
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
A Phase 3 study of Transthyretin Amyloid Cardiomyopathy, sponsored by Alexion Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 1,181
- Enrollment target
- 20
- Study locations
NCT06183931: Active Phase 3 study of Transthyretin Amyloid Cardiomyopathy, sponsored by Alexion Pharmaceuticals.
NCT06183931 is a Phase 3 study of Transthyretin Amyloid Cardiomyopathy that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 1,181 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06183931, a Phase 3 study of Transthyretin Amyloid Cardiomyopathy, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,181 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALXN2220
Study Locations (20)
California
- Research Site - Irvine
- Research Site - La Jolla
- Research Site - Palo Alto
- Research Site - San Francisco
New York
- Research Site - New York
- Research Site - New York
- Research Site - Stony Brook
Florida
- Research Site - Jacksonville
- Research Site - Weston
Georgia
- Research Site - Atlanta
- Research Site - Atlanta
Massachusetts
- Research Site - Boston
- Research Site - Boston
Missouri
- Research Site - Kansas City
- Research Site - St Louis
Colorado
- Research Site - Aurora
District of Columbia
- Research Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,181 participants |
| Start Date | 2024-01-11 |
| Est. Completion | 2027-10-05 |
| Phase | Phase 3 |
What the registry record for NCT06183931 still lists
NCT06183931 is an interventional study that assigns participants to a tested intervention. Its 1,181 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% higher).
The record links to 1 condition, with Transthyretin Amyloid Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06183931 names 20 study sites across 11 states, led by California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT06183931 about?
NCT06183931 is a clinical study titled "Study of ALXN2220 Versus Placebo in Adults With ATTR-CM". The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events...
What is the current status of trial NCT06183931?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,181 participants. The study started on 2024-01-11. Estimated completion is 2027-10-05.
What conditions does trial NCT06183931 study?
This clinical trial studies the following conditions: Transthyretin Amyloid Cardiomyopathy.
What interventions are being tested in trial NCT06183931?
The interventions under investigation include: Placebo (DRUG), ALXN2220 (DRUG).
Who is sponsoring clinical trial NCT06183931?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06183931 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloid Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06183931's enrollment target sits among peer trials
1,181 234th of 2000 higher than 1,767 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- NCT05688436 · 1,178 participants
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- NCT06931275 · 1,178 participants · NA
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI